Court Revives Zicam Complaint, But Says Disclosure Remains Case-by-Case
This article was originally published in The Tan Sheet
Executive Summary
An appellate court decision supporting a complaint against Matrixx Initiatives related to its over-the-counter cold remedy Zicam shows that determining what information firms must disclose is a "delicate," case-by-case process
You may also be interested in...
Supreme Court's Matrixx Decision Expands Firms' Disclosure Burden
The Supreme Court's decision in a complaint shareholders brought against Matrixx Initiatives lowers the threshold for when firms need to disclose information, but also aims to prevent an "avalanche of trivial information."
Matrixx Prompts Supreme Court To Consider What Firms Must Disclose
A class action suit against Zicam Cold Remedy maker Matrixx Initiatives heads to the Supreme Court, in a case that could affect the number of securities actions brought against pharma companies
Odds Are Stacked Against Matrixx In Bid To Rescind Zicam Warning Letter
Matrixx Initiatives faces long odds against convincing FDA to withdraw a warning letter concerning the firm's Zicam intranasal products, food and drug lawyers say after the firm's request was rejected a second time